Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more
Market Cap & Net Worth: Ascendis Pharma AS (ASND)
Ascendis Pharma AS (NASDAQ:ASND) has a market capitalization of $14.00 Billion ($14.00 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1312 globally and #999 in its home market, demonstrating a -4.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ascendis Pharma AS's stock price $228.06 by its total outstanding shares 61393156 (61.39 Million).
Ascendis Pharma AS Market Cap History: 2015 to 2026
Ascendis Pharma AS's market capitalization history from 2015 to 2026. Data shows growth from $1.12 Billion to $14.00 Billion (27.72% CAGR).
Index Memberships
Ascendis Pharma AS is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.62% | #27 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.04% | #184 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.90% | #17 of 263 |
Weight: Ascendis Pharma AS's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ascendis Pharma AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ascendis Pharma AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
18.93x
Ascendis Pharma AS's market cap is 18.93 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.24 Billion | $4.61 Million | -$68.50 Million | 269.78x | N/A |
| 2017 | $2.46 Billion | $1.53 Million | -$123.90 Million | 1607.46x | N/A |
| 2018 | $3.85 Billion | $10.58 Million | -$130.10 Million | 363.51x | N/A |
| 2019 | $8.54 Billion | $13.38 Million | -$218.02 Million | 638.58x | N/A |
| 2020 | $10.24 Billion | $6.95 Million | -$418.95 Million | 1472.62x | N/A |
| 2021 | $8.26 Billion | $7.78 Million | -$383.58 Million | 1061.87x | N/A |
| 2022 | $7.50 Billion | $51.17 Million | -$583.19 Million | 146.52x | N/A |
| 2023 | $7.73 Billion | $266.72 Million | -$481.45 Million | 28.99x | N/A |
| 2024 | $8.45 Billion | $363.64 Million | -$378.08 Million | 23.24x | N/A |
| 2025 | $13.09 Billion | $691.71 Million | -$219.03 Million | 18.93x | N/A |
Competitor Companies of ASND by Market Capitalization
Companies near Ascendis Pharma AS in the global market cap rankings as of March 18, 2026.
Key companies related to Ascendis Pharma AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Ascendis Pharma AS Historical Marketcap From 2015 to 2026
Between 2015 and today, Ascendis Pharma AS's market cap moved from $1.12 Billion to $ 14.00 Billion, with a yearly change of 27.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $14.00 Billion | +6.95% |
| 2025 | $13.09 Billion | +54.89% |
| 2024 | $8.45 Billion | +9.31% |
| 2023 | $7.73 Billion | +3.13% |
| 2022 | $7.50 Billion | -9.22% |
| 2021 | $8.26 Billion | -19.34% |
| 2020 | $10.24 Billion | +19.88% |
| 2019 | $8.54 Billion | +122.06% |
| 2018 | $3.85 Billion | +56.39% |
| 2017 | $2.46 Billion | +97.92% |
| 2016 | $1.24 Billion | +10.48% |
| 2015 | $1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ascendis Pharma AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.00 Billion USD |
| MoneyControl | $14.00 Billion USD |
| MarketWatch | $14.00 Billion USD |
| marketcap.company | $14.00 Billion USD |
| Reuters | $14.00 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.